Tengion's Days Sales Outstanding for the
three
months ended in Sep. 2014 was .
Tengion's Days Inventory for the
three
months ended in Sep. 2014 was .
Tengion's Days Payable for the
three
months ended in Sep. 2014 was .
Therefore, Tengion's Cash Conversion Cycle (CCC) for the
three
months ended in Sep. 2014 was 0.00.
Tengion Cash Conversion Cycle Historical Data
The historical data trend for Tengion's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tengion's Cash Conversion Cycle
For the Biotechnology subindustry, Tengion's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tengion's Cash Conversion Cycle Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tengion's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Tengion's Cash Conversion Cycle falls into.
Tengion Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Tengion's Cash Conversion Cycle for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Tengion Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Tengion's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNGNQ has been successfully added to your 